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Inducible T cell Co-stimulator (ICOS) is upregulated on lymphocytes following radiation of 
tumors and ICOS agonism in combination with radiation results in enhanced tumor control.
Michael J. Gough1, Shelly Bambina1, Monica Gostissa2, Christopher J. Harvey2, David J. Friedman3, Marka Crittenden1,4
1Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR, USA 2Jounce Therapeutics, Inc., Cambridge, MA, USA 
3Mayo Clinic Graduate School, Rochester, MN, USA 4The Oregon Clinic, Portland, OR, USA
Background
Abstract
Results Conclusions
Background: Radiation and co-stimulatory ligands or checkpoint inhibitors have demonstrated improved anti-
tumor immunity and overall survival in preclinical animal studies. However, the results of human trials suggest 
we have not yet found the optimal combination. Here we demonstrate upregulation of ICOS expression on T 
cells following focal tumor radiation and test the hypothesis that ICOS agonism in combination with radiation 
will enhance the immunologic effect of radiation resulting in increased survival. 
Methods: BALB/c mice bearing CT26 tumors or C57BL/6 mice bearing Panc02 tumors were treated at d14 
with 20Gy CT guided radiation therapy, and anti-ICOS antibody or isotype control antibody was administered 
i.p. Mice were followed for overall survival to 100 days post implantation. Animals were euthanized when 
tumors reached 1.2cm in greatest diameter. Flow cytometry was performed using a T cell panel on fresh whole 
blood, PBMC, or tumor infiltrating immune cells. 
Results: 24 hours following 20Gy focal radiation to a CT26 tumor there was a significant increase in the 
percent of circulating CD4 Treg that express ICOS in the blood (27.42% vs 18.02%, p<0.0001, n=5/group). 
Similarly, 7 days following radiation there was an increase in non-Treg CD4 cells expressing ICOS in the blood 
(7.73%  vs 3.68%, p<0.0001, n=5/group) and the tumor (62.16% vs 34.04%, p=0.004, n=5/group). ICOS 
expression was also increased on CD8 T cells in irradiated tumors (25.34% vs 14.02%, p=0.007). In mice 
bearing CT26 tumors, ICOS agonist antibody was administered prior to, concurrent with, or 7 days post 
radiation. Concurrent administration was associated with the most significant increase in survival (50%) when 
compared to isotype control (0%), ICOS agonist antibody alone (10%), or radiation plus isotype (0%). In the 
less immunogenic Panc02 tumor model, no survival benefit was seen with radiation and ICOS therapy. 
However in the same model, dual PD-1 antagonism and ICOS agonism plus radiation led to a significant 
increase in survival when compared to all other combinations, with an increase in median survival from 46 days 
to 68 days, p=0.01 compared to radiation alone and was associated with a 25% long term survival.
Conclusions: ICOS is upregulated on T cells following radiation and targeting ICOS in combination with 
radiation is associated with improved survival. Timing appears important as the benefit is optimal when ICOS 
agonism is delivered concurrent with radiation rather than preceding or 7 days post-radiation. In poorly 
immunogenic tumors, addition of PD-1 antagonism to the combination can lead to improved survival.
ICOS is upregulated on circulating CD25+ regulatory T cells 24 hours and on 
circulating effector T cell 7 days following radiation.
Figure 1: Balb/c mice were inoculated  in the flank with 2x105 CT26 cells. Radiation was delivered with a 
single tangential beam at a dose of 20 Gy on day 14. Blood was taken on days 7, 15, and 21. Flow 
cytometry was performed on whole blood. NT: no treatment, RT: radiation therapy. N=5/group. * p<0.05, 
** p<0.01, ***p<0.001, ****p<0.0001
Figure 2 : Balb/c mice were inoculated  in the flank with 2x105 CT26 cells. Radiation was delivered 
with a single tangential beam at a dose of 20 Gy on day 14. Tumors were harvested on day 21. 
Tumors were digested into single cell suspensions using a triple enzyme digest. Intratumoral cells 
were analyzed by flow cytometry. NT: no treatment, RT: radiation therapy. * p<0.05, ** p<0.01, 
***p<0.001, ****p<0.0001
Figure 3. : Balb/c mice were inoculated  in the flank with 2x105 CT26 cells. Radiation (RT) was 
delivered with a single tangential beam at a dose of 20 Gy on day 14. Isotype and anti-ICOS 
antibodies were administered at a dose of 0.25 mg/kg i.p. Timing of RT and antibody administration 
is illustrated in the diagram. N=10/group. Representative of 2 independent experiments. 
Figure 4.C57BL/6 mice were inoculated in the with a dose of 2x105 Panc02 cells. Radiation (RT) was 
delivered through a single tangential beam at a dose of 20Gy on day 14. Anti-ICOS Ab and Isotype 
Ab were administered i.p. at a dose of 0.25 mg/kg on days 14 and 21. Anti-PD1 Ab was administered 
i.p. at a dose of 250 ug/mouse on days 7,14 and 21. N=10/group. Representative of 2 independent 
experiments. 
Radiation causes an increase in CD25+ T regulatory cells 
and in ICOS+ effector T cells in the tumor.
ICOS agonist antibody treatment in combination with radiation 
improves survival. Concurrent administration is optimal.
ICOS agonist antibody in combination with radiation and PD-1 antagonism 
improves survival in poorly immunogenic tumors.
Balb/c
D0
CT26
D7 D8 D9 D10 D11 D14 D18D15 D16 D17 D21
Blood Blood
20Gy 
Blood
Balb/c
D0
CT26
D7 D8 D9 D10 D11 D14 D18D15 D16 D17
Harvest 
Tumors
D21
20Gy 
Balb/c
20Gy RTCT26 cells Sub Q
D0
D14 Follow for 
Survival
D10 D17D14 D21D18 D25
Early
Late
p=0.0021 p=0.0155
C57BL6
Panc02 cells Sub Q
Follow for 
Survival
D7 D14 D21
anti-ICOSanti-PD1
p=0.0215
• Radiation therapy of tumors is associated with modification of the local and systemic immune response
• Radiation therapy has shown synergy in preclinical models with both checkpoint inhibitors (anti-PD1, anti-
CTLA-4) as well as in combination with co-stimulatory molecules (anti-OX40, and 41BB)
• ICOS is an inducible co-stimulatory molecule that is expressed on activated T cells
• ICOS is a member of the CD28/CTLA4 family
• The ICOS agonist antibody JTX-2011 and other monoclonal Abs that target ICOS are in clinical development 
• The mouse surrogate of JTX-2011 used in this study has been previously shown to mediate dose dependent 
proliferation and activation of CD4 T effector cells and selective reduction of intratumoral T regulatory cells
• Through analysis of the phenotype of key T cells following radiation therapy we have identified 
ICOS as a novel target to modulate the immune response to radiation therapy. 
• There was an increase in survival associated with combined radiation treatment and ICOS 
agonist antibody administration, but only when treating with the ICOS antibody either 
concurrently with or after radiation. 
• In a less immunogenic tumor model the combination of PD-1 antagonist and ICOS agonist 
with radiation resulted in an increase in survival relative to either agent alone with radiation. 
Therefore, ICOS agonism may represent a new modality for combination immunotherapy of 
anti-PD-1 resistant tumors.
• The therapeutic efficacy of the ICOS agonist Ab appears to require RT-mediated modulation of 
the tumor immune infiltrate and induction of ICOS+ CD4 and CD8 T cells.
o The percentage of ICOS+ circulating CD4 T regulatory cells is increased within        
24 hours of focal tumor radiation.
o The percentage of ICOS+ circulating CD4 and CD8 T effector cells is increased         
7 days following focal tumor radiation.
o The percentage of ICOS+ intratumoral CD4 and CD8 T effector cells is increased      
7 days following focal tumor radiation.
o Although ICOS expression levels were not increased on these cells, focal tumor 
radiation also resulted in an increased percentage of intratumoral T regulatory cells.
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